LV5624A3 - Panemiens 5'-dezoksi-5-fluorcitidina atvasinajumu iegusanai - Google Patents

Panemiens 5'-dezoksi-5-fluorcitidina atvasinajumu iegusanai

Info

Publication number
LV5624A3
LV5624A3 LV930507A LV930507A LV5624A3 LV 5624 A3 LV5624 A3 LV 5624A3 LV 930507 A LV930507 A LV 930507A LV 930507 A LV930507 A LV 930507A LV 5624 A3 LV5624 A3 LV 5624A3
Authority
LV
Latvia
Prior art keywords
deoxy
contribution
obtaining
fluorocytidine derivatives
fluorocytidine
Prior art date
Application number
LV930507A
Other languages
English (en)
Inventor
Morio Fujiu
Hideo Ishitsuka
Masanori Miwa
Isao Umeda
Kazuteru Yokose
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of LV5624A3 publication Critical patent/LV5624A3/lv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
LV930507A 1987-11-17 1993-06-08 Panemiens 5'-dezoksi-5-fluorcitidina atvasinajumu iegusanai LV5624A3 (lv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP87116926 1987-11-17
SU884356869A SU1736342A3 (ru) 1987-11-17 1988-11-16 Способ получени производных 5 @ -дезокси-5-фторцитидина

Publications (1)

Publication Number Publication Date
LV5624A3 true LV5624A3 (lv) 1994-05-10

Family

ID=8197450

Family Applications (1)

Application Number Title Priority Date Filing Date
LV930507A LV5624A3 (lv) 1987-11-17 1993-06-08 Panemiens 5'-dezoksi-5-fluorcitidina atvasinajumu iegusanai

Country Status (35)

Country Link
US (1) US4966891A (lv)
EP (1) EP0316704B1 (lv)
JP (1) JPH0678350B2 (lv)
KR (1) KR970000241B1 (lv)
CN (1) CN1022688C (lv)
AR (1) AR247217A1 (lv)
AT (1) ATE124951T1 (lv)
AU (1) AU619220B2 (lv)
CA (1) CA1327358C (lv)
CS (1) CS274486B2 (lv)
DE (2) DE10199027I2 (lv)
DK (1) DK170893B1 (lv)
DZ (1) DZ1270A1 (lv)
ES (1) ES2074429T3 (lv)
FI (1) FI89804C (lv)
GR (1) GR3017686T3 (lv)
HK (1) HK1003114A1 (lv)
HU (1) HU199866B (lv)
IE (1) IE883430L (lv)
IL (1) IL88363A0 (lv)
IS (1) IS1895B (lv)
LT (1) LT2185B (lv)
LU (1) LU90769I2 (lv)
LV (1) LV5624A3 (lv)
MC (1) MC1992A1 (lv)
MX (1) MX173347B (lv)
NL (1) NL300045I2 (lv)
NO (2) NO171167C (lv)
NZ (1) NZ226923A (lv)
PH (1) PH25641A (lv)
PT (1) PT89009B (lv)
SU (1) SU1736342A3 (lv)
UA (1) UA19333A (lv)
YU (1) YU47122B (lv)
ZA (1) ZA888428B (lv)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258360B1 (en) * 1989-05-04 2001-07-10 Igen International, Inc. Prodrugs activated by targeted catalytic proteins
US5527782A (en) * 1990-03-13 1996-06-18 Acic (Canada) Inc. 5-halo-2,3'-O-cyclocytidines
TW254946B (lv) * 1992-12-18 1995-08-21 Hoffmann La Roche
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
US5476932A (en) * 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
EP0882734B1 (en) * 1997-06-02 2009-08-26 F. Hoffmann-La Roche Ag 5'-Deoxy-cytidine derivatives
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
US6005098A (en) * 1998-02-06 1999-12-21 Hoffmann-La Roche Inc. 5'deoxycytidine derivatives
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20010051348A1 (en) * 2000-01-28 2001-12-13 Lee Chee Wee Novel ligands and methods for preparing same
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
US6774758B2 (en) * 2002-09-11 2004-08-10 Kalyan P. Gokhale Low harmonic rectifier circuit
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
WO2004105747A1 (en) * 2003-05-20 2004-12-09 Aronex Pharmaceuticals, Inc Combination chemotherapy comprising capecitabine and a liposomal platinum complex
KR100851272B1 (ko) * 2003-12-22 2008-08-08 에프. 호프만-라 로슈 아게 플루오로시티딘 유도체에 대한 방법
WO2005080360A1 (en) * 2004-02-18 2005-09-01 Astrazeneca Ab Compounds
KR20070007103A (ko) * 2004-02-18 2007-01-12 아스트라제네카 아베 벤즈아미드 유도체 및 이의 글루코키나아제 활성화제로서의용도
CN100383128C (zh) * 2004-02-23 2008-04-23 上海迪赛诺医药发展有限公司 N4－氧羰基胞嘧啶衍生物及制备方法与应用
TW200600086A (en) * 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
KR101061850B1 (ko) 2004-09-08 2011-09-02 삼성전자주식회사 박막 트랜지스터 표시판 및 그 제조방법
GB0421294D0 (en) * 2004-09-24 2004-10-27 Angiogene Pharm Ltd Bioreductively-activated prodrugs
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
JP2008516935A (ja) 2004-10-16 2008-05-22 アストラゼネカ アクチボラグ フェノキシベンズアミド化合物の製造方法
WO2006084058A2 (en) 2005-02-03 2006-08-10 The General Hospital Corporation Method for treating gefitinib resistant cancer
NO322682B1 (no) * 2005-03-18 2006-11-27 Clavis Pharma Asa Anvendelse av gemcitabinderivater for fremstilling av orale doseringsformer ved kreftbehandling, samt slike orale doseringsformer
WO2006103187A2 (en) * 2005-04-01 2006-10-05 F. Hoffmann-La Roche Ag Method for administration of capecitabine
JP2008542247A (ja) * 2005-05-24 2008-11-27 アストラゼネカ アクチボラグ グルコキナーゼモジュレーターとしての２−フェニル置換イミダゾール［４，５ｂ］ピリジン／ピラジンおよびプリン誘導体
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
EP2027113A1 (en) * 2005-07-09 2009-02-25 AstraZeneca AB Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
BRPI0622262A2 (pt) 2005-07-09 2011-08-09 Astrazeneca Ab composto, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para a preparação de um composto
WO2007007040A1 (en) * 2005-07-09 2007-01-18 Astrazeneca Ab 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
CN100569790C (zh) * 2005-07-15 2009-12-16 上海奥锐特国际贸易有限公司 合成n4-酰基-5＇-脱氧-5-氟胞苷衍生物的方法
US20080292729A1 (en) * 2005-07-21 2008-11-27 Nuvo Research Inc. Stabilized Chlorite Solutions in Combination with Fluoropyrimidines for Cancer Treatment
US9202182B2 (en) * 2005-08-11 2015-12-01 International Business Machines Corporation Method and system for analyzing business architecture
US20070104721A1 (en) 2005-11-04 2007-05-10 Wyeth Antineoplastic combinations with mTOR inhibitor,herceptin, and/or hki-272
TW200738621A (en) 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
US20080085310A1 (en) * 2006-10-06 2008-04-10 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
TW200825063A (en) 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
TW200825060A (en) 2006-10-26 2008-06-16 Astrazeneca Ab Chemical compounds
CN100425617C (zh) * 2006-10-31 2008-10-15 浙江海正药业股份有限公司 一种含氟嘧啶类化合物烷氧羰酰化的方法
TW200833339A (en) 2006-12-21 2008-08-16 Astrazeneca Ab Novel crystalline compound
ITMI20070435A1 (it) 2007-03-05 2008-09-06 Innovate Biotechnology Srl 2',3'-di-o-acil-5-fluoronucleosidi
JP2010524960A (ja) * 2007-04-20 2010-07-22 ドクター・レディーズ・ラボラトリーズ・リミテッド カペシタビンを調製するためのプロセス
WO2008145403A1 (en) * 2007-06-01 2008-12-04 Synthon B.V. Processes related to making capecitabine
US8741858B2 (en) 2007-09-21 2014-06-03 Zhongxu Ren Oligomer-nucleoside phosphate conjugates
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
EP2225566A1 (en) * 2008-01-03 2010-09-08 Plus Chemicals S.A. Process for the preparation of capecitabine
EP2310011B1 (en) 2008-06-17 2013-07-24 Wyeth LLC Antineoplastic combinations containing hki-272 and vinorelbine
SI2326329T1 (sl) 2008-08-04 2017-06-30 Wyeth Llc Antineoplastične kombinacije 4-anilino-3-cianakinolinov in kapecitabina
PE20110568A1 (es) 2008-08-04 2011-09-07 Astrazeneca Ab Agentes terapeuticos 414
WO2010065586A2 (en) * 2008-12-02 2010-06-10 Dr. Reddy's Laboratories Ltd. Preparation of capecitabine
US8603999B2 (en) 2008-12-05 2013-12-10 Commonwealth Scientific And Industrial Research Organisation Amphiphile prodrugs
CN101787066B (zh) * 2009-01-23 2013-07-31 高峰 阿糖胞苷衍生物及其在抗癌抗肿瘤中的用途
GB0902434D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
GB0902406D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
HRP20230315T1 (hr) 2009-04-06 2023-05-12 Wyeth Llc Režim liječenja raka dojke korištenjem neratiniba
WO2010116176A1 (en) * 2009-04-09 2010-10-14 Astrazeneca Ab Pyrazolo [4, 5-e] pyrimidine derivative and its use to treat diabetes and obesity
AR076220A1 (es) 2009-04-09 2011-05-26 Astrazeneca Ab Derivados de pirazol [4,5 - e] pirimidina
CN101875680B (zh) * 2009-04-28 2012-07-25 上海信旗医药科技有限公司 一种核苷类化合物及其制备方法和应用
US20110021769A1 (en) * 2009-07-23 2011-01-27 Scinopharm Taiwan Ltd. Process for Producing Fluorocytidine Derivatives
HUE027831T2 (en) 2010-03-12 2016-11-28 Genzyme Corp Combination therapy for breast cancer
JP2015513913A (ja) 2012-04-02 2015-05-18 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ポリヌクレオチド
WO2013151666A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of biologics and proteins associated with human disease
CA2881068C (en) 2012-09-26 2021-06-08 F. Hoffmann-La Roche Ag Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
CN104955458A (zh) * 2012-11-07 2015-09-30 Z·索 取代的吉西他滨芳基酰胺类似物和使用所述类似物的治疗方法
WO2014152027A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Manufacturing methods for production of rna transcripts
EP2968382B1 (en) * 2013-03-15 2018-03-07 Nucorion Pharmaceuticals, Inc. Substituted gemcitabine bicyclic amide analogs and treatment methods using same
EP3041934A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Chimeric polynucleotides
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
CN103450301B (zh) * 2013-09-09 2015-09-09 南通大学 法尼基硫代水杨酸-核苷缀合物、其制备方法及其医药用途
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
JP6950972B2 (ja) * 2016-06-28 2021-10-20 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ ガンの処置のための組成物及び方法
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
CA3049435A1 (en) 2017-01-09 2018-07-12 Scott Grindrod Selective histone deacetylase inhibitors for the treatment of human disease
EP3618837A4 (en) 2017-04-26 2020-11-04 Thomas I. Kalman MULTI-DIRECTIONAL NUCLEOSIDE DERIVATIVES
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
CN112004537A (zh) 2018-01-09 2020-11-27 穿梭药业公司 用于治疗人疾病的选择性组蛋白去乙酰化酶抑制剂
CN111801339A (zh) * 2018-01-19 2020-10-20 纽科利制药公司 5-氟尿嘧啶化合物
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
US20210171564A1 (en) * 2018-08-03 2021-06-10 Cellix Bio Provate Limited Compositions and methods for the treatment of cancer
CN109651467A (zh) * 2019-01-15 2019-04-19 齐鲁天和惠世制药有限公司 一种卡培他滨杂质及其制备方法
CN115605492A (zh) 2020-04-21 2023-01-13 配体制药股份有限公司（Us） 核苷酸前药化合物
JP2023535225A (ja) 2020-07-24 2023-08-16 ストランド セラピューティクス インコーポレイテッド 改変ヌクレオチドを含む脂質ナノ粒子
US20240166707A1 (en) 2021-01-08 2024-05-23 Strand Therapeutics Inc. Expression constructs and uses thereof
WO2023212618A1 (en) 2022-04-26 2023-11-02 Strand Therapeutics Inc. Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3404144A (en) * 1965-12-23 1968-10-01 Research Corp 1-beta-d-arabinofuranosyl-5-fluorocytosine compounds
GB1379410A (en) * 1971-06-08 1975-01-02 Upjohn Co 1-beta-d-arabino-furanosyl-n4-alpha-aminoacylcytosines
JPS52153977A (en) * 1976-06-11 1977-12-21 Daikin Ind Ltd Synthesis of 5-fluorouracil and its derivatives
US4071680A (en) * 1976-12-20 1978-01-31 Hoffmann-La Roche Inc. 5'-Deoxy-5-fluoropyrimidine nucleosides
CH633810A5 (en) * 1978-01-01 1982-12-31 Hoffmann La Roche Novel nucleosides and process for their preparation
FR2528311B1 (fr) * 1982-06-14 1985-06-14 Synthelabo Compositions pharmaceutiques a base de xylosides et lyxosides de bases puriques et pyrimidiques
JPS61112093A (ja) * 1984-11-05 1986-05-30 Wakunaga Seiyaku Kk ヌクレオチド誘導体

Also Published As

Publication number Publication date
CN1022688C (zh) 1993-11-10
AU619220B2 (en) 1992-01-23
NL300045I2 (nl) 2002-01-02
HK1003114A1 (en) 1998-10-09
LU90769I2 (fr) 2001-07-02
ES2074429T3 (es) 1995-09-16
NO885106L (no) 1989-05-18
SU1736342A3 (ru) 1992-05-23
ATE124951T1 (de) 1995-07-15
CA1327358C (en) 1994-03-01
DK640388D0 (da) 1988-11-16
NZ226923A (en) 1990-10-26
DK640388A (da) 1989-05-18
HU199866B (en) 1990-03-28
EP0316704A3 (en) 1990-11-22
KR970000241B1 (ko) 1997-01-08
PT89009B (pt) 1993-02-26
NO171167B (no) 1992-10-26
UA19333A (uk) 1997-12-25
IE883430L (en) 1989-05-17
NL300045I1 (nl) 2001-08-01
YU209188A (en) 1990-08-31
DE10199027I1 (de) 2001-08-02
CS274486B2 (en) 1991-04-11
PH25641A (en) 1991-08-21
GR3017686T3 (en) 1996-01-31
AR247217A1 (es) 1994-11-30
FI885329A (fi) 1989-05-18
EP0316704A2 (de) 1989-05-24
PT89009A (pt) 1988-12-01
DE10199027I2 (de) 2002-01-31
ZA888428B (en) 1989-06-28
FI89804C (fi) 1993-11-25
NO2001013I2 (no) 2006-05-01
CN1033183A (zh) 1989-05-31
AU2516888A (en) 1989-05-25
MX13836A (es) 1993-10-01
FI89804B (fi) 1993-08-13
DE3854148D1 (de) 1995-08-17
JPH0678350B2 (ja) 1994-10-05
HUT48267A (en) 1989-05-29
JPH01153696A (ja) 1989-06-15
DZ1270A1 (fr) 2004-09-13
MC1992A1 (fr) 1989-11-30
NO885106D0 (no) 1988-11-16
LT2185B (lt) 1993-10-15
DK170893B1 (da) 1996-03-04
NO171167C (no) 1993-02-03
FI885329A0 (fi) 1988-11-17
IS3412A7 (is) 1989-05-18
YU47122B (sh) 1994-12-28
IL88363A0 (en) 1989-06-30
IS1895B (is) 2003-10-20
KR890008162A (ko) 1989-07-10
MX173347B (es) 1994-01-03
EP0316704B1 (de) 1995-07-12
CS747588A2 (en) 1990-09-12
US4966891A (en) 1990-10-30

Similar Documents

Publication Publication Date Title
LV5624A3 (lv) Panemiens 5'-dezoksi-5-fluorcitidina atvasinajumu iegusanai
DK434088A (da) Epipodophyllotoxinglucosid-4'-phosphatderivater
DE3856154D1 (de) Adenosin-Derivate
DK54488A (da) Adenosin-5'-carboxamid-derivater
TR26815A (tr) Azolilmetil-sikropil türevleri
DK564088A (da) Nukleosidderivater
TR24894A (tr) N-FENILPIRAZOL TüREVLERI
DK507188A (da) Cholecalciferolderivater
DK378088A (da) Alkenderivater
DK49688A (da) Propiolophenonderivater
DK71187A (da) Purinderivater
DK702688D0 (da) Epipodophyllotoxin-glucosid 4'-acylderivater
DK271088A (da) Tienopyridinderivater
MC1918A1 (fr) Derives de l'imidazodiazepine
DK695788A (da) Naphtalenderivater
FR2602233B1 (fr) Derives de l'isoquinoleine
DK733688D0 (da) Dioxazocinderivater
DK71488D0 (da) Dipenylethylen-derivater
FR2603282B1 (fr) Derives d'isoquinoleine
MC1816A1 (fr) Derives d'isoquinoleine
ATA87988A (de) Pflugnachlaeufer
ES2022963B3 (es) Arado
DK204089A (da) Plov
ATA78088A (de) Pflugnachlaeufer
DK313789A (da) Thiadiazinonderivater